Lassomycin - NovoBiotic Pharmaceuticals

Drug Profile

Lassomycin - NovoBiotic Pharmaceuticals

Latest Information Update: 25 Jun 2016

Price : $50

At a glance

  • Originator Northeastern University
  • Developer Northeastern University; NovoBiotic Pharmaceuticals
  • Class Anti-infectives; Peptides
  • Mechanism of Action Endopeptidase Clp inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 24 Apr 2014 Preclinical trials in Tuberculosis in USA (unspecified route) before April 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top